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To generate  a  humoral  T  cell-dependent  immune  response  to  a  soluble  protein 
antigen, at least three distinct classes of immunocompetent cells--antigen presenting 
cells,  T  cells,  and  B  cells--must interact  in  a  concerted  manner  (1-4).  During  the 
initial part of this interaction, soluble antigen is thought to be taken up by Ia-positive 
antigen-presenting  cells  (APC) 1  (presumably  macrophages  or  dendritic  cells)  and 
processed before being presented to antigen-reactive T  helper cells. The APC processes 
the  protein  antigen  in  a  way  that  both  native  and  denatured  forms of the  same 
protein exhibit a high degree of cross-reactivity to antigen-reactive T  helper cells (5). 
This observation suggests that a protein antigen may be denatured and/or degraded 
during antigen processing. Antigen-reactive T  helper cells are thought to recognize a 
specific  restriction  site  on  the  Ia  molecules  that  are  expressed  by  the  APC  in 
conjunction  with  a  specific  determinant  on  the  processed  protein  antigen  (6-8). 
Whether  the  Ia and processed  antigen  are  physically associaed  or separate on  the 
APC  plasma membrane is still a  controversial issue. After recognition,  the antigen- 
reactive T  cells become activated T  cells  that  can  interact  with  B  cells directly or 
indirectly  through  soluble  mediators to initiate  B  cell differentiation  and  antibody 
production.  Although a considerable amount of data has been published concerning 
many  aspects  of antigen  presentation,  the  biochemical  events  that  occur  during 
antigen  processing  and  those  that  control  APC-TH  cell  interactions  are  largely 
unknown.  This is  due  in  great  part  to an  inability  to  purify sufficient  numbers  of 
homogeneous APC. 
We describe a  series of tumor lines that are capable of presenting soluble protein 
antigens  to  antigen-reactive  continuous  T  cell  lines  in  a  major histocompatibility 
complex  (MHC)-restricted  fashion.  These  tumor  cells  express  both  I-A  and  I-E 
subregion Ia antigens and have the phenotypic characteristics of lymphocytes rather 
than macrophages or dendritic  cells. The characterization  of the antigen-presenting 
functions of the tumor cells presented in this report indicate that the tumor cells have 
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many of the  functional antigen-presenting characteristics previously thought  to be 
limited to maerophages, The tumor cells should be a  very useful model system for 
determining the biochemical events that occur in antigen-processing and  for deter- 
mining the potential interactions between processed antigen and Ia molecules on the 
plasma membrane of these APC, 
Materials and Methods 
Mice,  DBA/2, C57BL/6, and (A/J ×  C57BL/6)F~  (B6A) mice were purchased from The 
Jackson Laboratory, Bar Harbor, Maine, or were bred in the Mayo Clinic animal facilities, 
Tumor Cells.  WEHI 5, WEHI 3, WEHI 231, WEHI 265.1, WEHI 265, and HUCL-1 tumor 
cells were grown in culture media consisting of Dulbecco's minimum essential medium (Gibco 
Laboratories,  Grand Island Biological Co,, Grand Island, N, Y,), 15% fetal calf serum  (or 15% 
horse serum), 3 ×  10  -n M 2-mercaptoethanol, 12 mM Hepes, 100 U/ml penicillin and 100 fig/ 
ml  streptomycin, and  2  x  l0  ~  M  glutamine.  The LIOA2J  tumor line  is  a  subllne  of' the 
spontaneous  L10A BALB/c lymphoma originally  described  by Kim et al,  (9). The original 
L10A tumor cells were reported to express both/.i and g immunoglobulln chains,  The L10A 
cells that we obtained express cytoplasmic s chain but not/~ chain (Dr, M, Kuehl, personal 
communication), The L10A2J subllne was selected for enhanced espression of I-A subregion la 
antigens  with a radioimmunoassay,  using the monoclonal 17/227  (anti-Ia,15)  antibody, The 
tumor cells were grown in culture media consisting of RPMI  1640 (Qibeo Laboratories),  10% 
horse serum, 3 ×  10  -~ M 2-mercaptoethanol, 12 mM Hepes,  !00 U/ml penicillin  and  100 ~g 
streptomycin,  and 2 x  !0  -~ M  L-glutamine. The T2 and D2N virally induced cell lines (10) 
were generously provided by Dr. B Chesebro  (Rocky Mt. Laboratory, Hamilton, Moat.), The 
strain of origin  and phenotypic characteristics  of each of these cell lines are summarized in 
Table I, A detailed description of the cell surface phenotypic markers of these cell lines and the 
biochemical characterization of their la antigens  is described elsewhere? 
Antisera,  The  17/227  (anti-la.15),  116,32 (antl.Ia.19),  and  13/18  (and.Ia,7)  monoclonal 
antibodies  (11) are all Ig(3~ immunoglobullns  obtained from Dr, G, Hammerling, Heidelberg, 
Germany, The monoclona! antibodies  were purified on protein A Sepharose  (12) and used at 
TABLE I 
Phenotypic Characteristics of Tumor Cells Tested  for Antigen Presentation 
Ia Anti-  Phago-  a-Napthyl**  Anti~¢I~ 
Tumor cell*  Strain of origin  Tumor designation  gens:~  FcyR§  cvtosixl[  [g¶  buty~atc  pl't'~it'lltit- 
•  ~wrasc  d,m** 
I,IOA2J  BAI,B/c  B Lymphoma  ++  +  -  k§§  -  + 
WEHI 5  (BALB/c X NZB)FI  B l,ymphoma  ++  +  -  p., k  1-~')~-t"  + 
T2  BAI,B/c  I.eukemia  +  +  -  -  -  + 
WEHI 231  (BALB/c ×  NZB)FI  B 1.ymphoma  +  +  -  #, k  ~  4- 
D2N  DBA/2  Leukemia  ++  +  -  -  -  + 
WEHI 265  BAI.B/c  Monocytic leukemia  :;k  N1)]]][  ND  -  ND  ::t: 
WEHI 265.1  BALB/c  Monocytic leukemia  -  ND  NI)  -  +  - 
HUCL-I  BALB/c  Monocytic  -  ND  ND  -  NI)  - 
WEHI 3  BALB/c  Monocytic  -  ND  N|)  -  NI)  - 
All tumor line~ art: Bonadheren~  in ia vitro cqlt~re. 
1~ ~ndgens  were isolated from It:pti]  let:tin purifi*:d, [:!HI!eu  Tritop ~10~ so]ubilized ",:~]] e~tr~,t:~, pro~ipit~,~ed whh  (BI0.GD  g  lt~llPi imtidtl0HGT 
(an~i-|  ~) alloantiser/4 and fluantitv~tt:d  ~n ~D$-PAGF. (I 3).  Amounts ,~f l~ are !ehttive to all~t~ts i~l~t~  fi'om BAld!/c ~plewat:yu:~  (,¢'+)  Nov ~cxU, 
§ EA (sheep t:rythrocyte)  rosette assay (9). 
l[ Latex partlc]t: !1. l/i) ingestion verified by electron  microscopy (9): 
¶ lg cell surface t:~pre~ion dete[mioed by flUorescencv activated cell sortef  (30), 
** a-Napthyl butyrate estera.se  stai0 dQoe actc~rding to ]~i et al. (all 
:~* This paper. 
§§ Personal communlcatio0, Dr. M, Kueh[, Univefslty of Virginia• 
IIII Not do.e. 
2 E. Walker,  L. L. Lanier, N, L. Warner, and D, J. McKeam Characterization and functional properties 
of B !ymph~ma ~nd Me# tumor cell lint~s in ~cces~ory  cell replacement assays, Manuscript submitted for 
publication, McKEAN  ET AL.  1421 
a concentration of 1 mg/ml. The (BI0.LG ×  B6)F1 anti-B10.HTG (anti-Ia), A.TH anti-A.TL, 
and (B10.LG X C3H/HEJ)FI anti-C3H.OL (anti-H-2D  d) alloantisera were generously provided 
by Dr. Chella David, Mayo Clinic, 
Antigens.  Sperm whale myoglobin (rob) was purchased from Sigma Chemical Co., St. Louis, 
Mo. and was purified by ion exchange chromatography (13). CAT (lot  10) was purchased from 
Miles Laboratories, Inc., Elkhart, Ind. 
Lipopolysaccharide (LPS)  Stimulation.  Tumor cells at 5 ×  106/ml  were stimulated with LPS 
(14)  at  50 pg/ml  for 48  h  and  then  washed  free  of LPS before being added  to the T  cell 
proliferation assay. 
Soluble Antigen-reactive T Cell Cultures.  The antigen-reactive T cells were induced as previously 
described (15). A detailed report (16) on the establishment and maintenance of rob-reactive T 
cell  lines  will  be  reported  elsewhere.  The  T  cells  are  maintained  as  long-term  continuous 
cultures  by restimulation  at  10-14-d intervals with  antigen  and syngeneie irradiated  (3,300 
tad)  spleen  cells.  Viable  antigen-reactive  T  cells  were  recovered  10-14  d  after  antigenic 
restimulation and used to assay specific antigen presentation by splenic or tumor APC. In this 
assay,  10  ~ T  cells were mixed with  10  e spleen or  105 tumor cells  that  had been treated with 
either mitomyein C (107 cells/ml treated with 50 #g mitomycin C for 30 min at 37°C) or 3,300 
rad  of y-irradiation  (laTCs source,  Isomedix).  Cells  were  incubated  in  0.2  ml  RPMI  1640 
medium (described above but containing 10% fetal calf serum) containing 1-3 #M antigen in 
microtiter  plates  (3040;  Falcon  Labware,  Oxnard  Calif.)  for 48  h  at  37°C.  [3H]thymidine 
(Research Products International Corp., Mr. Prospect, Ill.; 2 #Ci/well) was then added to each 
well, the cells were harvested  16 h later on filter paper, and 3H incorporation was quantitated 
with standard liquid scintillation counting. All assays were done in triplicate, and the standard 
deviations of each mean value were within  15%. Antigen-pulsed presenting cells were prepared 
by incubating 1-2 #M mb and  10 ×  106 tumor or spleen cells for 2 h. The cells were washed 
three times in Hanks' balanced salt solution, treated with either mitomycin-C or y-irradiation, 
and assayed with the antigen-reactive T cells, as described above. The d haplotype cells used in 
these experiments are high responders to both mb (17) and CAT (18). 
Antiserum Treatment of Antigen Proliferation Cultures.  Alloantiserum inhibition of T  cell prolif- 
eration cultures was done by mixing comparable amounts of specific anti-Ia or control sera in 
the T  cell proliferation assay.  Mb-specific T cell proliferation was shown to be independent of 
any residual Ia-positive cells in the T cell cultures by treating the T cell population with A.TH 
anti-A.TL serum and complement. The cells  (10 ×  106 to 20 x  106/ml)  in medium  199 2% 
horse serum were mixed with 100 btl A.TH anti-A.TL for 30 min at 4°C, washed three times in 
medium  199 2% horse serum, and resuspended at  10 ×  106 to 20 x  106 cell/ml in medium 199 
containing 1:10 dilution of rabbit serum (complement source)  for 1 h at 37°C. The treated cells 
were  washed,  counted,  and  added  to  the  T  cell  proliferation  assay.  A  similar  anti-Ia  plus 
complement treatment  of DBA/2 spleen,  L10A2J, or WEHI 5 cells  was done in parallel  to 
demonstrate the effectiveness  of the anti-Ia/complement-mediated cytotoxicity. 
Results 
Soluble Antigen-reactive  T  Cells.  The highly enriched antigen-reactive T  cells used in 
these experiments were grown as long-term continuous cultures.  Previous reports  (16) 
on similarly derived antigen-reactive T  cells have demonstrated that they are capable 
of providing T  helper cell  functions  in an in vitro plaque  assay  (R.  Hodes,  and  M. 
Kimoto, personal communication)  and their proliferative response is antigen specific 
and  MHC  (I region)  restricted.  Table II shows that  the DBA/2 mb-reactive T  cells 
are only stimulated  in  the presence of antigen-presenting  spleen  cells  that  share  the 
H-2 a haplotype  (DBA/2,  B10.D2).  The fact  that  neither  B6  (H-2 b)  nor A/J spleen 
cells ( K~I-A k I-B ~ l-J k I-E k I-C a S a D a) present mb to the DBA/2 mb-reactive T  cells 
provisionally  maps  the  genetic  restriction  requirements  of these T  cells  between  K a 
and  LE a.  Similarly  derived  mb-reactive  B6A long-term cultured  T  cells  and T  cell 1422  B LYMPHOCYTE  TUMOR  CELLS  PRESENT  ANTIGEN 
TABLE II 
MHC Restriction of DBA/2 et mb T Cells* 
Antigen-presenting 
spleen cells of strain 
[3H]Thymidine incorporation 
Without mb  With mb 
DBA/2  1,640  28,673 
BI0.D2  1,965  28,372 
B6  1,338  2,249 
B6A  5,598  2,454 
A/J  1,149  997 
* Tumor or spleen cells were mixed  (in triplicate)  with  1 ~M  mb and  10  4 
antigen-reactive T ceils. [SH]thymidine was added after 2 d of culture, and 
the cells were harvested on day 3. 
TABLE III 
Tumor Cell Antigen Presentation 
APC 
[SH]Thymidine incorporation 
DBA/2 a mb T cells  DBA/2 a GAT T cells 
Without  With  Without  With 
mb  mb  GAT  GAT 
WEHI 265,1 *  3,089  3,787  2,881  2,513 
WEHI 3*  655  607  ND H 
HUCL-I*  574  473  ND 
WEHI 5:~§  2,804  17,575  3,702  20,346 
L 10A2J~:  4,283  15,513  5,544  22,103 
WEHI 231:1:§  224  7,378  561  21,368 
T2:~§  2,362  15,510  3,541  25,714 
D2N:~§  1,666  13, 715  5,719  24,956 
WEHI 265:~  11,269  15,401  7,214  12,373 
DBA/2 Spleen*  1,545  39,047  976  60,207 
* Irradiated (3,300 rad). 
Mitomycin-C treated. 
§Tumor  cells  treated  with  mitomyin-C  induced  a  similar  amount  of antigen-specific 
[SH]thymidine incorporation with DBA/2 antigen-reactive T cells. 
II Not done. 
clones required sharing of the I-A or I-E and I-A subregion between the APC and T 
cells to generate antigen-specific T  cell proliferation (A. Infante, unpublished results). 
Selection  of Tumor  Cells  That  Present  Antigen.  In  this  laboratory,  during  the  past 
several years,  a  number  of tumor  cells have  been  screened  for  the  expression of Ia 
antigens  by  biochemically  isolating  intrinsically  radiolabeled  Ia  molecules.  These 
tumor  cell  lines  were  also  assayed  for  their  ability  to  present  soluble  antigen  to 
antigen-reactive T  cells in a T  cell proliferation assay (Table III). Initial experiments 
indicated  that  the  tumor  cell  lines  pretreated  with  y-irradiation  or  mitomycin-C 
allowed comparable  levels of antigen-specific T  cell proliferation  (data not  shown). 
The L10A2J line was an exception to this in that we were unable to inhibit intrinsic 
[3H]thymidine incorporation with previous 3,-irradiation. Consequently,  the L10A2J 
line was  always assayed after  mitomycin-C  treatment.  Tumor  cells that  would  not 
allow antigen-specific T  cell proliferation could not be shown by biochemical analysis 
to express  detectable levels of Ia antigens.  One  possible exception  to  this  is WEHI McKEAN  ET  AL.  1423 
265, which expresses small amounts of Ia antigens and which induced only marginally 
significant antigen-specific T cell proliferation. The two tumor lines that were initially 
shown to allow antigen-specific T  cell proliferation (L 10A2J and WEHI 5) were used 
in all subsequent experiments to characterize the specificity of this antigen-presenting 
function. 
Kinetics  of Responses.  To optimize the T  cell proliferation assay with  the  tumor 
cells, either the amounts of antigen or the numbers of antigen-presenting tumor cells 
were titrated with a constant number of mb-reactive DBA/2 T  cells.  Fig.  1 A shows 
that  when  L10A2J,  WEHI  5,  or  DBA/2  spleen  cells  are  used  to  present  varying 
amounts of mb to mb-reactive T  cells, optimal T  cell proliferation is produced with 
1/~M rob. When the amount of mb and number ofT cells were held constant and the 
number  of tumor  or spleen  cells  were  varied,  maximum  T  cell  proliferation  was 
produced  with  105-106  spleen  and  105  tumor  cells  (Fig.  1B).  In  both  titration 
experiments, the tumor lines and spleen cells gave qualitatively and  quantitatively 
similar dose-response curves. 
Antigen-pulsedPresenting  Cells.  Previous studies (1) that used adherent macrophage- 
like  cells  as  APC  have  shown  that  antigen-specific  T  cell  proliferation  could  be 
generated if the antigen was either present throughout the assay period or if the APC 
were first incubated (,pulsed)  with the antigen, washed to remove unbound antigen, 
and  then added to the antigen-reactive T  cells.  To determine whether these tumor 
cells required the constant presence of soluble antigen to generate antigen-specific T 
cell proliferation, we incubated the tumor cells with mb for 2 h and washed unbound 
antigen from the cells before adding them to the mb-reactive T  cells. Table IV shows 
that the pulsed WEHI 5 tumor cells induced a T  cell proliferative response that was 
equal to or better than the response generated when the antigen was present in the 
culture medium throughout the assay period. Similar results have also been obtained 
with pulsed L10A2J tumor cells (data not shown). 
MHC  Restriction.  It  has  previously been  demonstrated  (6-8)  in  several different 
species that soluble protein antigen can be effectively presented to antigen-reactive T 
cells by an APC  only if the T  cell and  APC  share a  common I-region allele.  The 
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FIG.  1.  Titration  of the quantity of (A) mb and (B)  antigen-presenting cells needed to generate 
maximum levels of antigen-specific T  cell proliferation. In both experiments the antigen-presenting 
cells were treated with mitomycin-C before assay with 10  4 DBA/2 mb-reactive T  cells. 1424  B  LYMPHOCYTE  TUMOR  CELLS  PRESENT  ANTIGEN 
TABLE  IV 
Anti-la  Treatment  of Different Cell Populations  That Are Necessary for T  Cell Proliferation Assay 
APC  Antigen-reactive T 
cell (10 4) 
3H incorporated 
Without  With  Antigen 
mb  mb  pulsed* 
WEHI 5 (105)  DBA/2 amb  2,535  12,519  20,705 
WEHI 5 (10~  DBA/2 a mb~  1,666  21,257  28,791 
LIOA2J  (105)  DBA/2 a  mb  5,695  10,467  ND§ 
L10A2J  (10  ~)  DBA/2 a mb~  4,056  11,817  ND 
DBA/2 spleen  (105)  DBA/2 amb  969  45,437  36,701 
DBA/2 spleen (105):]:  DBA/2 a mb  435  4,384  ND 
DBA/2 spleen  (106)  DBA/2 a mb~  1,651  64,637  ND 
DBA/2 spleen (106)~:  DBA/2 a mb~  319  9,594  ND 
* Antigen-pulsed cells were incubated with  1 /LM mb for 2 h, washed,  irradiated, and added to the assay 
wells. 
~: Cells were treated with anti-Ia (A.TH a  A.TL) (I-A  a +  LE  d) and rabbit complement before assay. The 
treatment killed  96+%  of WEHI 5 and L10A2J tumor cells. Similar results  have been obtained using 
(BI0 X D2.GD)  a  BI0.5R instead  of A.TH a  A.TL anti-Ia. Irradiated spleen,  irradiated WEHI 5, or 
mitomycin-C treated L10A2J  cells were mixed in triplicate with 1 #M mb and  104 DBA/2 rob-reactive 
T cells. 
§ ND, Note done. 
TABLE  V 
Antigen Presentation by Tumor Cells to Syngeneic and Allogeneic 
rob-reactive T  Cells 
APC  Antigen-reactive 
T cell (104) 
aH incorporation 
Without  With 
mb  mb 
A.  WEHI 5 (10s)~  DBA/2 a mb  1,283  29,013 
DBA/2 spleen  (106)§  DBA/2 amb  1,282  18,530 
WEHI 5 (105)~:  B6A amb  1,581  930 
B6A spleen  (105)§  B6A a mb  657  62,578 
B.  LIOA2J  (105):[:  DBA/2 a mb  1,343  7,974 
LPS LIOA2J  (105)~:  DBA/2 a mb  2,213  12,115 
DBA/2 spleen  (105)§  DBA/2 a  mb  1,776  16,735 
L10A2J  (10~)~:  B6A amb  1,211  1,449 
LPS LIOA2J  (105)~  B6A amb  1,774  1,685 
B6A spleen  (105)§  B6A a mb  1,233  53,281 
* Groups A and B were assayed on different  days. 
:~ Mitomycin C-treated (50 ktg for 30 rain). 
§ Irradiated (3,300 rad). 
antigen-reactive  T  cells are thought  to  recognize an  I-region-encoded  restriction  site 
in  addition  to  a  specific antigenic  determinant  to generate T  cell proliferation  (6,  8, 
16). To determine whether these tumor cells could present  antigen in a  similar MHC- 
restricted fashion, several different antigen-reactive T  cell cultures, each with reactivity 
to  different  antigens  and/or  different  I-region-encoded  restriction  sites,  were  stimu- 
lated with antigen  and  antigen-presenting  tumor cells. The data  in Tables  III and V 
demonstrate  that  both  L10A2J  and  WEHI  5  tumor  cells can  effectively present  the 
appropriate  antigen  to DBA/2  mb-reactive T  cells and  DBA/2  GAT-reactive T  cells 
but  not  to B6A rob-reactive T  cells. McKEAN  ET  AL.  1425 
Studies done both in vitro (19,  20)  and  in vivo (21)  have demonstrated that  the 
addition  of anti-Ia  antisera  to  APC-T  cell cultures  can  be  used  to  block antigen 
recognition by T  lymphocytes. If the  antigen  presentation  function of WEHI  5  is 
similarly MHC-restricted, antigen-specific T  cell proliferation should be blocked by 
the addition of anti-I  a antibodies to the proliferation assay. Because the responding 
T  cells in  our assay system are  not cloned there could be T  cells present  that  are 
restricted to Ia antigens  encoded in  the I-A subregion  (Ap  d A~  d)  and  other T  cells 
restricted to Ia antigens encoded in I-E (Ae  d E~  d)  (Table II; and A. Infante, personal 
communication). Thus, monoclonal antibodies with reactivity to I-A d or LE a subre- 
gion Ia antigens could be expected to only partially block mb-specific T  cell prolif- 
eration. Alloantisera specific to all/d-region Ia antigens should completely block the 
antigen-specific T  cell  proliferation.  This  predicted  pattern  of blocking  of T  cell 
proliferation by anti-Ia antibodies was observed when the WEHI 5 cells were used as 
APC  (Table VI). The addition of either monoclonal anti-Ia.7 (I-E) or alloanti-Ia.23 
(I-E) to the antigen presentation assay partially blocked T  cell proliferation, whereas 
the addition of (B10.LG ×  B6)F1 anti-B10.HTG (anti-/a) serum completely blocked 
T  cell  proliferation.  In  contrast,  comparable  amounts  of  monoclonal  anti-Ia.15 
monoclonal (A#  d A~d), anti-Ia. 19 (unreactive with Ae  d E~  d or A#  d A~d), anti-H-2D a or 
normal mouse serum did not significantly block the antigen-specific T  cell prolifera- 
tion. 
To clarify the site of action of the anti-Ia sera, the APC or the antigen-reactive T 
cells were treated with A.TH anti-A.TL and complement before they were added to 
the proliferation assay. This anti-Ia treatment killed >96% of the WEHI-5 or L 10A2J 
tumor cells. When the DBA/2 spleen cells were treated with anti-Ia and complement, 
the antigen-specific T  cell proliferative response was reduced by 91% (Table IV). In 
contrast, when the DBA/2 spleen, L10A2J, or WEHI 5 cells were used to present mb 
TABLE VI 
Blocking  WEHI 5 Antigen  Presentation to rob-reactive DBA/2  T 
Cells with Antisera * 
Percent of control 
Antisera  3H incorporation  response:~ 
NMS§  18,562  100 
Anti-Ddl  20,098  108 
Anti-Ia. 19¶  16,546  89 
Anti-Ia.15**  16,579  89 
Anti-Ia.7:l:~  10,637  57 
Anti-la.23§§  10,870  58 
Anti-Id.][l]  328  1 
* Antisera was added to the T cell proliferation assay at the beginning of the 
culture period. 
The percentage is equal to [aH]thymidine incorporation of experimental/ 
[SH]thymidine incorporation of normal mouse serum control. 
§ Normal DBA/2 mouse serum, 2 #1. 
[I A.TFR-1 anti-A.TL, 2 #1. 
¶ 116.32 monoclonal, 5/tl (1 mg/ml). 
** 17/227 monoclonal, 5 #1 (1 mg/ml). 
*$ 13/4 monoclonal, 5 #1 (1 mg/ml). 
§§ (B10.LG X C3H/HEJ)F1 anti-C3H.OL, 2 #1. 
IIII (B10.LG X B6)F1 anti-Bl0.HTG, 2 #1. 1426  B  LYMPHOCYTE  TUMOR  CELLS  PRESENT  ANTIGEN 
to anti-Ia-treated mb-reactive T  cells, there was  no reduction in antigen-specific T 
cell proliferation. The apparent enhanced proliferative response (Table IV) obtained 
when tile DBA/2 spleen or WEHI 5 APC were assayed with anti-Ia-treated T  cells 
rather than untreated T  cells has not been consistently observed. 
Discussion 
It is widely accepted that the cells that present soluble antigen to T  helper cells in 
vitro and in vivo in an MHC-restricted fashion are radioresistant, adherent, phago- 
cytic immunoglobulin (Ig)-negative, Fc y-receptor-positive, and Ia-positive cells that 
belong  to  the  macrophage  lineage  (22).  Steinman  and  Nuzzenzweig  (23)  have 
presented  evidence that  suggests  that  lymphoid  dendritic  cells  that  are  adherent, 
nonphagocytic, Ig negative, Fc-y receptor-negative, and Ia-positive are also effective 
at presenting antigen. Data are presented in this paper that demonstrate that a series 
of Ia-positive tumor cells with the phenotypic characteristics of B lymphocytes can 
also present antigen in vitro to antigen-reactive T  cells. The experiments presented in 
this paper were designed to examine whether antigen presentation by these tumor 
cells was functionally similar to antigen presentation previously attributed to macro- 
phages. The data from these experiments suggest that the tumor cells can effectively 
bind soluble antigen and present it to antigen-reactive T  cells in an MHC-restricted 
fashion. 
One requisite function of an APC is the ability to physically bind soluble antigen 
independent of cytophilic antibody before antigen processing and subsequent presen- 
tation to antigen-reactive T  cells (24-26). Adherent macrophage-like APC that have 
been  incubated  (pulsed)  with  the  antigen  for relatively short  periods of t~me  and 
washed  free  of unbound  antigen  will  effectively generate  antigen-specific  T  cell 
proliferation in vitro (1). The WEHI 5 (Table IV) and L10A2J tumor cells (data not 
shown) that have been pulsed with mb generated specific T  cell proliferation that was 
44-98% greater than the proliferative response produced when the antigen was present 
in solution throughout the assay period. In contrast, DBA/2 spleen cells pulsed with 
antigen under similar conditions usually produced a T  cell proliferative response that 
was equal to or slightly less than that produced when antigen was present throughout 
the assay. The significance of this difference is not known. The ability to use pulsed 
tumor cells to generate antigen-specific T  cell proliferation should, in future analyses, 
enable us to separate the biochemical events of antigen uptake and processing from 
antigen  presentation  and  T  cell  recognition  in  this  tumor  cell  antigen-presenting 
system. 
The  tumor  cells  tested  for  antigen  presentation  function  are  all  of the  H-2 a 
haplotype (BALB/c, DBA/2, or (BALB/c ×  NZB)F~ and therefore should potentially 
be capable of presenting antigen only to antigen-reactive T cells that share 1-1-2 ~. The 
data in Tables III and V  demonstrate that although WEHI 5 and L10A2J can allow 
antigen-specific  proliferation  from  DBA/2  rob-reactive  T  cells  or  DBA/2  GAT- 
reactive T  cells, the same tumor cells cannot allow mb-specific proliferation of B6A 
mb-reactive T  cells.  If the  antigen-reactive  T  cells  were  recognizing an  I-region- 
encoded determinant on the tumor cells in addition to antigen, we should be able to 
block antigen-specific T  cell proliferation with  anti-Ia sera.  The data  in  Table VI 
show  that  (B10.GD  ×  B6)F1  anti-B10.HGT  (anti-I  d)  completely  blocks  antigen- 
specific T  cell proliferation when WEHI 5 cells are used as APC, whereas comparable McKEAN ET AL.  1427 
amounts of control sera  (normal  mouse serum or anti-H-2D a)  do not  significantly 
decrease the T  cell proliferative response when WEHI 5 cells are used as APC. Table 
VI shows that  monoclonal anti-Ia.7  (I-E) or aUoanti-Ia.23  (I-E) partially block the 
antigen-specific T  cell proliferative response when the WEHI 5 cells are used as APC. 
The absence of significant blocking by the anti-Ia. 15 monoclonal antibody could be 
due to the absence of a significant number of DBA/2 T  cells reactive with the region 
of the I-A subregion Ia molecule that is physically adjacent to the Ia. 15 alloantigenic 
determinant. Preliminary MHC restriction experiments on T cell clones isolated from 
our DBA/2 mb-reactive T  cells suggests that  there are at least some mb-reactive T 
cells restricted to I-A a as well as 1-A a/I-E a in our T  cell population. Additionally, the 
WEHI  5  tumor  cells  are  capable  of presenting  antigen  to  both  types  of MHC- 
restricted T  cell clones (data not shown). 
Schwartz  et  al.  (27)  published  data  that  indicated  that  an  Ia-positive BALB/c 
tumor cell (A20) could function in a peritoneal exudate T  lymphocyte subpopulation 
(PETLES) assay to induce antigen-specific T  cell proliferation. However, this T  cell 
proliferation was eliminated if the antigen-reactive T  cells were treated with anti-Ia 
and complement. Schwartz et al.  (27) interpreted these results as indicating that the 
tumor cell was not presenting antigen directly to the antigen-reactive T  cell but was 
transferring the antigen to an Ia-positive cell in the PETLES antigen-reactive T  cell 
population.  This  second  Ia-positive  cell  could  presumably  function  to  effectively 
present the antigen to the antigen-reactive T  cells. 
To determine whether a  similar  phenomena was  occurring with  the  L10A2J  or 
WEHI  5  tumor  cells,  we  treated  the  antigen-reactive  T  cells  with  anti-Ia  and 
complement  before testing  with  spleen  or  tumor  cells  in  the  antigen-presentation 
assay. Data in Table IV show that such anti-Ia pretreatment of the antigen-reactive 
T  cells showed no significant decreased proliferation when antigen was presented by 
the L 10A2J, WEHI 5, or DBA/2 spleen cells. The effectiveness of the anti-Ia treatment 
was  demonstrated  by similarly treating either the  DBA/2  spleen cells,  L10A2J, or 
WEHI 5 tumor cells with anti-Ia and complement. Greater than 96% of either the 
L10A2J or WEHI 5 tumor cells were killed by this treatment. Anti-Ia treatment of 
the DBA/2 antigen-presenting spleen cells killed 40-50% of the DBA/2 spleen cells 
and decreased the antigen-specific T  cell proliferative response by >90%. These data 
indicate that if there are any residual Ia-positive cells in our antigen-reactive contin- 
uous T  cell cultures, they do not play a significant role in antigen presentation by the 
tumor cells. These data also demonstrate that  the target cell in the anti-Ia blocking 
of T  cell proliferation (Table IV) is probably the APC and not the responding T  cell. 
An  important  question that  remains unanswered  concerns the biological signifi- 
cance of antigen presentation by normal Ia-positive lymphocytes. These five tumor 
lines,  which  can  be  shown  to  synthesize  Ia  antigens,  all  allow  antigen-specific 
proliferation in antigen-reactive T  cells.  The phenotypic markers expressed by these 
cells  (Table  I,  reference  28)  indicate  that  four  of the  five  lines  are  not  of the 
macrophage lineage. Although there have been previous reports (1, 29, 30) suggesting 
that highly enriched populations ofB lymphocytes were capable of presenting antigen 
to T  cells,  the  presence of small  numbers  of contaminating  macrophage-like APC 
could  never be excluded. The data presented  in  this  paper suggest  that  a  normal 
lymphocyte subpopulation  represented by these  tumor cell  lines  may exist  in  vivo 
that are capable of presenting antigen to T  helper cells. 1¢28  B LYMPHOCYTE TUMOR CELLS PRESENT ANTIGEN 
The titration of the numbers of spleen cells or tumor cells required to generate a 
maximum  T  cell proliferative response  (Fig,  1)  suggests  that  an  equal  number of 
spleen or tumor cells are needed to generate a comparable T cell proliferative response. 
Because macrophages represent only a small percentage of spleen cells, these titration 
data appear to suggest that the tumor cells are not as efficient on a per cell basis at 
presenting antigen. Although this conclusion might prove to be correct, the potential 
heterogeneity of the tumor cells should be considered before it is concluded that the 
antigen  presentation  phenomena  exhibited  by these  tumor cells  has  no  biological 
significance.  First,  these  tumor  lines  that  have been  grown  in  in  vitro culture  for 
several years are not cloned cells.  Second, we have observed that at least some of the 
tumor lines have the tendency to modulate their levels of expression of Ia antigens 
when maintained in in vitro culture for extended periods. For example, the WEHI 
265.1  subline was maintained in in vitro culture for several years and lost its ability 
to express Ia antigens.  The parent  WEHI  265  line that  was  recovered after being 
frozen clearly expresses Ia. The tumor cell lines are currently being subcloned and 
will  be  tested  to  determine  whether  the  level  of Ia  antigen  expression  or  other 
phenotypic markers  can  be  correlated with  the  cell's  ability  to  effectively present 
antigen. 
The tumor cell lines might, on the other hand,  be deficient in certain functions 
(e.g., mediator production) that are expressed by macrophages or possibly third party 
cells and are necessary for optimal antigen presentation to antigen-reactive T  helper 
cells.  For example, when WEHI 5 or L10A2J tumor cells were stimulated with LPS 
for 2 d before being used as APC, the antigen-specific T  cell proliferative response to 
DBA/2 mb-reactive T  cells was increased by 40-50% (Table V). This was shown not 
to be a nonspecific effect of residual LPS inasmuch as B6A mb-reactive T  cells were 
not stimulated by the LPS-treated L10A2J cells.  LPS stimulation increased the total 
amount of Ia antigens synthesized by L10A2J and WEHI 5 cells by an average of 
50% (D. J.  McKean, unpublished observations) and also might potentially increase 
the expression of mediators  (31).  Experiments are in progress to determine whether 
cloned tumor APC require other soluble mediators to more effectively present antigen 
to cloned antigen-reactive T  cells. 
Tumor  cells  have  historically  provided  a  means  of viewing  functions  of select 
subpopulations of cells within the immune system. The results of the experiments in 
this  report  demonstrate  that  WEHI  5  and  L10A2J  tumor cells  exhibit  the  major 
functions previously attributed  to macrophage APC.  They are capable of binding 
antigen and presenting the cell-associated antigen in conjunction with Ia determinants 
to antigen-reactive T  cells.  Once these tumor cells are cloned, they should provide a 
valuable  model  system  for  examining  the  biochemical  basis  for  antigen  uptake, 
processing, and Ia-associated antigen presentation to cloned antigen-reactive T  cells. 
The data presented in this paper also suggest the need for a critical examination of 
normal subpopulations within the routine immune system to determine exactly which 
cells can present soluble antigen. 
Summary 
Previous reports have demonstrated that accessory cells function to present soluble 
protein antigens in association with gene products encoded within the I region of the 
major  histocompatibility  complex  (MHC)  to  antigen-reactive T  helper  cells.  The McKEAN  ET AL.  1429 
biochemical  events  that  occur  during  antigen  presentation  are,  however,  not  well- 
documented  primarily  because  of the  difficulties  involved  in  purifying  sufficient 
numbers  of homogeneous  antigen-presenting  cells.  In  this  paper,  a  number  of Ia- 
positive  B  lymphocyte tumor  lines  are  shown  to  be  capable  of presenting  soluble 
protein  antigens  to  antigen-reactive  continuous  T  cell  lines  in  an  MHC-restricted 
fashion. The characterization of the antigen presentation function of these tumor cells 
indicates  that  the tumor cells have many of the  functional antigen-presenting  char- 
acteristics previously thought to be limited to macrophages. These tumor cells should 
provide a  useful model system for determining the biochemical events that occur in 
antigen  uptake  and  processing as well  as for determining  the  potential  interactions 
between  processed  antigen  and  Ia  molecules  on  the  plasma  membrane  of these 
antigen-presenting cells. 
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